RUBY - Rubius Therapeutics Inc
Previous close
0.057
0 0%
Share volume: 755,858
Last Updated: Fri 29 Dec 2023 06:00:00 AM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$0.06
0.00
0.00%
Fundamental analysis
6%
Profitability
0%
Dept financing
7%
Liquidity
50%
Performance
0%
Performance
5 Days
185.00%
1 Month
198.43%
3 Months
251.85%
6 Months
171.43%
1 Year
-17.87%
2 Year
-17.87%
Key data
Stock price
$0.06
DAY RANGE
$0.06 - $0.06
52 WEEK RANGE
$0.00 - $0.12
52 WEEK CHANGE
-$0.18
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Pablo Cagnoni
Region: US
Website: https://www.rubiustx.com/
Employees: 0
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: https://www.rubiustx.com/
Employees: 0
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
developing a novel enucleated cell (ecell)(tm) therapy platform for unmet medical needs. founded by flagship venturelabs.
Recent news